pharma · Triple Negative Breast Cancer (TNBC) · Mesothelin-Expressing Tumors · CNTX
Context Therapeutics
Context Therapeutics is a pharma organization headquartered in Philadelphia, USA. It trades on NYSE under ticker CNTX. Primary therapeutic focus areas include Triple Negative Breast Cancer (TNBC), Mesothelin-Expressing T
Philadelphia, USA HQ
2015 Founded
26 Employees
Public company Type
CNTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Philadelphia, USA
- Founded
- 2015
- Employees
- 26
- Programs
- 8
- Drugs
- 7
- Patents
- 3
Extended-release Onapristone
Phase 2 · small molecule · Refractory Endometrial Adenocarcinoma
Extended-release Onapristone for Refractory Endometrial Adenocarcinoma is a Phase 2 program (small_molecule) at Context Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 20P.829
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Context Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Refractory Endometrial Adenocarcinoma
- Status
- active
- Trials
- 1